| 51 |
29876677 | Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This? | 2018 Jun 6 |
1 |
| 52 |
30150888 | The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers. | 2018 |
6 |
| 53 |
30210640 | Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials. | 2018 |
2 |
| 54 |
30310287 | Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis. | 2018 |
3 |
| 55 |
30373679 | Diffusion-weighted MR imaging of locally advanced breast carcinoma: the optimal time window of predicting the early response to neoadjuvant chemotherapy. | 2018 Oct 29 |
2 |
| 56 |
30428932 | Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. | 2018 Nov 14 |
1 |
| 57 |
30570890 | Adding anthracycline plus cyclophosphamide to adjuvant paclitaxel plus trastuzumab might be more reasonable in stage I hormone receptor negative HER-2 positive breast cancer patients. | 2018 Sep-Oct |
1 |
| 58 |
26874836 | Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer. | 2017 Jan |
2 |
| 59 |
27530622 | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. | 2017 May |
1 |
| 60 |
28005247 | Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. | 2017 Feb |
1 |
| 61 |
28190761 | Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. | 2017 Jul |
1 |
| 62 |
28335887 | Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. | 2017 Mar |
1 |
| 63 |
28413662 | Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer. | 2017 Apr |
2 |
| 64 |
28693173 | Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. | 2017 Jul |
1 |
| 65 |
28736636 | Biological agents in gastrointestinal cancers: adverse effects and their management. | 2017 Jun |
1 |
| 66 |
29089804 | The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population. | 2017 Oct |
2 |
| 67 |
29132326 | Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer. | 2017 Nov 13 |
1 |
| 68 |
29190955 | Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial. | 2017 Nov 3 |
1 |
| 69 |
29262565 | A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy. | 2017 Nov 28 |
3 |
| 70 |
29323058 | Assessment of topoisomerase II-alpha gene status by dual color chromogenic in situ hybridization in a set of Iraqi patients with invasive breast carcinoma. | 2017 Oct-Dec |
1 |
| 71 |
26836985 | Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? | 2016 May 3 |
1 |
| 72 |
26992012 | Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction. | 2016 Apr |
3 |
| 73 |
26998288 | Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα. | 2016 Mar |
1 |
| 74 |
27091714 | Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. | 2016 Jul 10 |
2 |
| 75 |
27611952 | Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. | 2016 Oct 18 |
1 |
| 76 |
27721532 | Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials. | 2016 Sep-Oct |
1 |
| 77 |
27920624 | Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years. | 2016 Oct |
1 |
| 78 |
27932758 | [Expressions of HER2 and Topo IIα in breast cancer and
its clinical significance]. | 2016 Nov 28 |
2 |
| 79 |
28174484 | Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study. | 2016 Dec |
2 |
| 80 |
24769570 | The role of anthracyclines in the treatment of early breast cancer. | 2015 Jun |
2 |
| 81 |
25467313 | Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab. | 2015 Feb |
1 |
| 82 |
25748080 | HER2-positive metastatic breast cancer: a changing scenario. | 2015 Jul |
1 |
| 83 |
25825476 | Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). | 2015 Jul 1 |
2 |
| 84 |
26394326 | Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers. | 2015 |
2 |
| 85 |
26711981 | [Clinical efficacy and safety of trastuzumab plus capecitabine as first-line therapy for HER-2 positive metastatic breast cancer]. | 2015 Sep 8 |
1 |
| 86 |
26752929 | Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer. | 2015 Dec |
4 |
| 87 |
24682655 | HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. | 2014 May |
1 |
| 88 |
24803548 | In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer. | 2014 Jul |
1 |
| 89 |
24803887 | Cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen as adjuvant chemotherapy for breast cancer. | 2014 Feb |
2 |
| 90 |
25041784 | HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancer. | 2014 Sep 30 |
2 |
| 91 |
25068025 | Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines. | 2014 Jul 26 |
1 |
| 92 |
25218596 | EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. | 2014 Dec 1 |
1 |
| 93 |
25301539 | The trastuzumab and vinorelbine combination: an alternative to taxane-based chemotherapy for early-stage and locally advanced her2-positive breast cancer. | 2014 Oct |
2 |
| 94 |
25379022 | Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. | 2014 Oct |
2 |
| 95 |
25512030 | Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. | 2014 Dec 15 |
3 |
| 96 |
25642443 | The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset. | 2014 Dec |
3 |
| 97 |
23103368 | Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer. | 2013 Feb |
2 |
| 98 |
23233651 | Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. | 2013 May |
1 |
| 99 |
23341518 | Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. | 2013 Mar 1 |
1 |
| 100 |
23344713 | All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. | 2013 Apr |
1 |